Use of [-2] pro PSA and phi index for early detection of prostate cancer: A prospective of 452 patients;Place du -2proPSA et de l'index phi dans la détection précoce du cancer de prostate: Évaluation sur une série de 452 patients

Progres en Urologie

Volumn 22, Issue 5, 2012, Pages 279-283

  Houlgatte, A ^a   Vincendeau, S ^b   Desfemmes, F ^a   Ramirez, J ^a   Benoist, N ^a   Bensalah, K ^b   Durand, X ^a  

^a University of Paris Descartes   (France)

^b RENNES UNIVERSITY HOSPITAL   (France)

Author keywords

Phi index; Prostate cancer; PSA isoform

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BLOOD; COMPARATIVE STUDY; EARLY DIAGNOSIS; HUMAN; MALE; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROSTATE TUMOR; SENSITIVITY AND SPECIFICITY;

EARLY DIAGNOSIS; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 84859850333     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2011.09.009     Document Type: Article

References (9)

1. Durand X., Xylinas E., Ploussard G., De la Taille A. Biomarqueurs urinaires de la prostate. Prog Urol 2010, 20:1184-1191.
2. Postma R., Schroder F.H. Screening for prostate cancer. Eur J Cancer 2005, 41:825-833.
3. Sokoll L.J., Wang Y., Feng Z., et al. (-2) proPSA for prostate cancer detection: an NCI early detection research network validation study. J Urol 2008, 180:539-543.
4. Pelzer A.E., Volgger H., Bektic J., et al. The effect of percentage free prostate specific antigen (PSA) level on the prostate cancer detection rate in a screening population with low levels. BJU 2005, 96:935-938.
5. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of the percentage of free prostate specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998, 279:1542-1547.
6. Le B.V., Griffin C.R., Loeb S., et al. (-2) proPSA is more accurate than total and free PSA in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol 2010, 183:1355-1359.
7. Jansen F.H., van Schaik R.H.N., Kurstjens J., et al. Prostate-specific antigen (PSA) isoform in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010, 57:921-927.
8. Raaijmakers R., Blijenberg B.G., Finlay J.A., et al. Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness. J Urol 2004, 171:2245-2249.
9. Catalona W.J., Bartsch G., Rittenhouse H.G., et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4ng/ml prostate specific antigen. J Urol 2004, 171:2239-2244.